BRAIN (Biomarker Rapid Assessment of Ischemic iNjury)
1 other identifier
observational
900
5 countries
22
Brief Summary
This project is designed to evaluate the clinical utility of a novel blood test, the Triage Stroke Panel, as an aid in the diagnosis and assessment of stroke. The Triage Stroke Panel test device, used with the Triage MeterPlus, is a rapid, point-of-care immunoassay. The test measures the concentration of various analytes present in EDTA-anticoagulated whole blood or plasma, specifically B-type natriuretic peptide (BNP), fibrin degradation products containing D-Dimer, matrix metalloproteiase-9 (MMP-9), and S-100B. The test utilizes a proprietary algorithm for the automatic calculation of a single Multimarker Index (MMX) result from the individual biomarker values. The MMX result is being evaluated for use as an aid in the assessment and diagnosis of stroke.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
22 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2002
CompletedFirst Submitted
Initial submission to the registry
September 13, 2005
CompletedFirst Posted
Study publicly available on registry
September 21, 2005
CompletedJuly 22, 2015
July 1, 2015
September 13, 2005
July 20, 2015
Conditions
Eligibility Criteria
Cerebral ischemia or intracranial hemorrhage suspected.
You may qualify if:
- Age 18 and above Cerebral ischemia or intracranial hemorrhage suspected Enrollment within 24 hrs from symptom onset or last well-known time
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (22)
Alabama Neurological Institute
Birmingham, Alabama, 35209, United States
University of California, Los Angeles Medical Center
Los Angeles, California, 90095, United States
Denver Health
Denver, Colorado, 80204, United States
University of Colorado Health Science Center
Denver, Colorado, 80262, United States
Hartford Hospital
Hartford, Connecticut, 06102, United States
OSF Saint Francis Medical Center
Peoria, Illinois, 61637, United States
Kentucky Neuroscience Research
Louisville, Kentucky, 40202, United States
University of Massachusettes, Worcester Medical Center
Worcester, Massachusetts, 01655, United States
Henry Ford Health System
Detroit, Michigan, 48202, United States
Ingham Regional Medical Center
Lansing, Michigan, 48823, United States
Henepin County Medical Center
Minneapolis, Minnesota, 55415, United States
St. Luke's Health System
Kansas City, Missouri, 64111, United States
Duke University Hopsital
Durham, North Carolina, 27710, United States
University of Cincinnati
Cincinnati, Ohio, 45267, United States
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
Hospital at the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
Sentara Norfolk General Hospital
Norfolk, Virginia, 23507, United States
Toronto Western Hospital
Toronto, Ontario, M5T 2S8, Canada
Neurologische Universitatsklinik/Heidelberg
Heidelberg, Germany
CHUV-Lausanne
Lausanne, Switzerland
University of Nottingham
Nottingham, NG5 1PB, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Daniel Laskowitz, MD
Duke University Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 13, 2005
First Posted
September 21, 2005
Study Start
July 1, 2002
Last Updated
July 22, 2015
Record last verified: 2015-07